Anti Pd 1 Antibodies - Cancer Science

Relevant Publications

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).

Issue Release: 2024

Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types.

Issue Release: 2024

Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma.

Issue Release: 2024

PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET.

Issue Release: 2024

Immunotherapy for esophageal cancer: Where are we now and where can we go.

Issue Release: 2024

Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers.

Issue Release: 2024

Adjuvant PD-1 Checkpoint Inhibition in Early Cutaneous Melanoma: Immunological Mode of Action and the Role of Ultraviolet Radiation.

Issue Release: 2024

GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy.

Issue Release: 2024

Inhalable metal-organic framework-mediated cuproptosis combined with PD-L1 checkpoint blockade for lung metastasis synergistic immunotherapy.

Issue Release: 2024

Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?

Issue Release: 2024

Targeting tumorous Circ-E-Cadherinencoded C-E-Cad inhibits the recruitment and function of breast cancer-associated myeloid-derived suppressor cells.

Issue Release: 2024

Immune checkpoint inhibitors: breakthroughs in cancer treatment.

Issue Release: 2024

Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity.

Issue Release: 2024

Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.

Issue Release: 2024

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors.

Issue Release: 2024

Functional diversification of innate and inflammatory immune responses mediated by antibody fragment crystallizable activities against SARS-CoV-2.

Issue Release: 2024

Opaganib Downregulates N-Myc Expression and Suppresses In Vitro and In Vivo Growth of Neuroblastoma Cells.

Issue Release: 2024

Kikuchi disease: A case report about Sintilimab-induced Kikuchi histiocytic necrotizing lymphadenitis and literature review.

Issue Release: 2024

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.

Issue Release: 2024

Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective study.

Issue Release: 2024

How Do Accommodations Impact Mental Health?

How Does NLR Compare with Other Biomarkers?

How Does Solubility Impact Drug Formulation?

When Should You Consult Your Doctor About Pain?

Can Patients Administer These Injections Themselves?

What Are the Future Directions in HER2 Research?

Can external factors be controlled or mitigated?

How Reliable is EMG for Cancer Patients?

What Are the Symptoms of Zygomycetes Infections?

How Do Benefit Concerts Support Cancer Research?

Anti Pd 1 Antibodies - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics